Covid-19: Oxford-AstraZeneca coronavirus vaccine shows 70% efficacy, can be 90% effective, finds data

Oxford University and pharmaceutical giant AstraZeneca said on Monday that the coronavirus vaccine being developed by them has shown 70 per cent efficiency. Oxford-AstraZeneca further said that the vaccine could be around 90 per cent effective under “one dosing regimen”.

A press note released by the Oxford University stated, “Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens”.

“In the two different dose regimens, vaccine efficacy was 90% in one, and 62% in the other,” the release on interim trial data from Phase III trials further said.

“Early indication that vaccine could reduce virus transmission from an observed reduction in asymptomatic infections,” it added.

The Oxford release also mentioned that there were no hospitalised or severe cases in anyone who received the vaccine.

Oxford and AstraZeneca are waiting for the results of phase III trials of their coronavirus vaccine candidate ‘AZD1222’ on thousands of people around the world to show whether their vaccine is safe and effective.

“These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world,” Professor Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the Oxford Vaccine Trial, was quoted as saying in the press note.

READ  Developed countries inch closer to annual global climate finance goal

Vaccine breakthroughs

Oxford-AstraZeneca findings come days after two other drugmakers, Pfizer and Moderna, reported preliminary results from late-stage trials showing that their Covid-19 vaccines were almost 95% effective.

The coronavirus vaccine developed by Pfizer has shown 95 per cent efficacy in the late-stage trial, the company said earlier this month.

The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.

Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94 per cent.

Meanwhile, Moderna also last week announced that its experimental Covid-19 vaccine ‘mRNA-1273’ was 94.5 per cent effective in preventing coronavirus. The statement was issued on the basis of interim data from a late-stage clinical trial.

Covid-19: Oxford-AstraZeneca coronavirus vaccine shows 70% efficacy, can be 90% effective, finds data